Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Receivables (2016 - 2025)

Integra Lifesciences Holdings' Change in Receivables history spans 17 years, with the latest figure at $16.5 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 47.71% year-over-year to $16.5 million; the TTM value through Dec 2025 reached $485000.0, up 106.56%, while the annual FY2025 figure was $485000.0, 106.56% up from the prior year.
  • Change in Receivables for Q4 2025 was $16.5 million at Integra Lifesciences Holdings, up from -$22.5 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $31.5 million in Q4 2024 and bottomed at -$28.8 million in Q3 2024.
  • The 5-year median for Change in Receivables is $4.2 million (2022), against an average of $756700.0.
  • The largest YoY upside for Change in Receivables was 6784.68% in 2024 against a maximum downside of 12734.82% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $10.2 million in 2021, then decreased by 1.35% to $10.0 million in 2022, then tumbled by 95.45% to $457000.0 in 2023, then surged by 6784.68% to $31.5 million in 2024, then plummeted by 47.71% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Change in Receivables are $16.5 million (Q4 2025), -$22.5 million (Q3 2025), and $28.0 million (Q2 2025).